On-demand webinar Evaluation of HER2-low and ultralow status of advanced breast carcinomas

Watch this webinar to discover how digital pathology with AI evaluation is a more sensitive method for HER2-low assessment. Dr. Anikó Kovács (Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden) presents findings from a retrospective study on the HER2-low status of advanced breast carcinomas in core biopsies. 

The aim of the study was to:

  • compare the outcome of HER2 scoring using conventional microscopy, digital pathology, and AI.
  • assess changes in HER2-low status in core biopsies, matching operation specimens, and their distant metastases.

Learn more about the findings and how AI can help determine a more accurate HER2-low status, providing an exact percentage of each HER2 score within seconds with high accuracy.

Aniko Kovacs_portrait_square

Anikó Kovács, MD, PhD Associate Professor, Pathologist, and Lecturer at Sahlgrenska University Hospital

  • Has worked in research in Sweden for the past 23 years
  • Breast cancer research at the Leicester University in the UK
  • Research background also in Japan (Kitasato University) and Hungary
Rute P_portrait_500x500px

Rute Pedrosa, PhD Senior Field Application Scientist, Aiforia Technologies

  • Has worked at Aiforia for 2.5 years
  • PhD at Erasmus University Rotterdam, focusing on the pathogenesis of brain metastatic disease

Watch the on-demand webinar

On-demand webinar

Evaluation of HER2-low and ultralow status of advanced breast carcinomas

Intro to Aiforia
00:25
Presentation by Dr. Anikó Kovács
04:18
Q&A
31:36